Evolent Health (EVH) Common Equity (2014 - 2026)

Evolent Health's Common Equity history runs 13 years deep, the most recent figure standing at $396.4 million for Q1 2026.

• On a quarterly basis, Common Equity fell 57.63% year-over-year to $396.4 million in Q1 2026; TTM through Mar 2026 was $396.4 million, a 57.63% decrease from a year earlier, with the FY2025 full-year figure at $415.2 million, down 58.53% from the prior year.
• Common Equity fell to $396.4 million in Q1 2026 per EVH's latest filing, from $415.2 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2023 and bottomed at $396.4 million in Q1 2026.
• The 5-year median for Common Equity is $935.5 million (2025), against an average of $879.2 million.
• Across the five-year window, Common Equity soared 83.53% in 2023 and tumbled 58.53% in 2025, its largest moves.
• Year by year, Common Equity stood at $859.4 million in 2022, then increased by 24.24% to $1.1 billion in 2023, then fell by 6.22% to $1.0 billion in 2024, then tumbled by 58.53% to $415.2 million in 2025, then dropped by 4.53% to $396.4 million in 2026.
• Per Business Quant, the three latest EVH Common Equity figures stand at $396.4 million (Q1 2026), $415.2 million (Q4 2025), and $842.2 million (Q3 2025).